Ciprofloxacin pharmacokinetics in critically ill patients receiving concomitant continuous venovenous hemodialysis.
Vanderbilt University, Nashville, Tennessee.
Matthew S
MS
Shotwell
Vanderbilt University, Nashville, Tennessee.
Phillip N
PN
Madonia
Emory University, Atlanta, Georgia.
Michael J
MJ
Connor
Cleveland Clinic, Cleveland, Ohio.
Milen
M
Amde
Cleveland Clinic, Cleveland, Ohio.
Charbel
C
Salem
Cleveland Clinic, Cleveland, Ohio.
Olufemi A
OA
Aduroja
Cleveland Clinic, Cleveland, Ohio.
Seth R
SR
Bauer
Vanderbilt University, Nashville, Tennessee.
Joseph J
JJ
Groszek
Vanderbilt University, Nashville, Tennessee. Electronic address: william.fissell@vanderbilt.edu.
William H
WH
Fissell
D000368:Aged; D000900:Anti-Bacterial Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D019540:Area Under Curve; D001424:Bacterial Infections / Q000188:drug therapy / Q000401:mortality; D002939:Ciprofloxacin / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D016638:Critical Illness / Q000401:mortality; D004305:Dose-Response Relationship, Drug; D004352:Drug Resistance, Microbial; D005260:Female; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D011446:Prospective Studies; D006435:Renal Dialysis / Q000379:methods*
D000900:Anti-Bacterial Agents; D002939:Ciprofloxacin